“Efficacy and Safety of Tislelizumab Plus Lenvatinib As First-Line Treatment in Patients With Unresectable Hepatocellular Carcinoma ”. Medical Forum Monthly 35, no. 6 (June 30, 2024). Accessed February 1, 2026. https://medicalforummonthly.com/index.php/mfm/article/view/4698.